NCT06767813

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Multi-cohort, Open, Phase II Clinical Study of TQB2868 Injection Combined With Arotinib Capsule and Chemotherapy in the First-line Treatment of Pancreatic Neoplasms

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms

Conditions

• Pancreatic Neoplasms

Interventions

Type	Name	Description
DRUG	TQB2868 injection	TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.
DRUG	Gemcitabine injection	Gemcitabine injection
DRUG	Albumin paclitaxel injection	Albumin paclitaxel injection
DRUG	Anlotinib capsules	Anlotinib capsules

Timeline

• Start date: 2024-03-19
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2025-01-10
• Last updated: 2025-09-19

Locations

7 sites across 1 country: China